Safety Tolerability and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection

  • days left to enroll
  • participants needed
  • sponsor
    Arbutus Biopharma Corporation
Updated on 24 July 2021


This three-part, Phase 1 protocol will be the first clinical study of AB-836. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-836 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-836 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.

Condition Chronic hepatitis
Treatment Placebo, Tenofovir disoproxil fumarate, AB-836
Clinical Study IdentifierNCT04775797
SponsorArbutus Biopharma Corporation
Last Modified on24 July 2021


Yes No Not Sure

Inclusion Criteria

Healthy Subjects
Male subjects or female subjects not of childbearing potential between 18 and 45 years old
Free from clinically significant illness or disease as determined by their medical history, physical examination, vital signs, and clinical laboratory test results
BMI of 18-32 kg/m2
CHB Subjects
Male or female between 18 and 65 years old
Chronic HBV infection documented as a positive HBsAg, HBV DNA, or HBeAg test at least 6 months prior to the Screening Visit, or a historical liver biopsy consistent with chronic HBV infection
For cohort F, G, H and J
HBV DNA 2,000 IU/mL at Screening (subjects may be either treatment-nave or treatment-experienced but currently off-treatment)
For Cohort I
HBV DNA <LLOQ at Screening
Subjects must have been receiving either TAF, TDF, or ETV consistently for 6 months prior to Day 1 and are willing to continue with the same NA treatment through the final study visit
ALT 2.5 x ULN
HbsAg 250 IU/mL at screening

Exclusion Criteria

CHB Subjects
Advanced fibrosis, cirrhosis or other signs of advanced liver disease as assessed by clinical history, ultrasound or FibroScan, or history of cirrhosis or any clinically significant medical condition associated with chronic liver disease
Co-infection with HIV or other non-B hepatitis viruses
Any clinically significant or unstable medical condition or illness that could confound study findings
Subjects who are unwilling to comply with protocol contraception requirements, and female subjects who are pregnant or breastfeeding
Previous treatment with a capsid inhibitor, core inhibitor, or core protein assembly modifier [CpAM or CAM]) within 6 months of the Day 1 visit, or prior treatment with an HBV-targeted siRNA or antisense oligonucleotide compound at any time
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note